Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ERDAFITINIB vs ERTUGLIFLOZIN PIDOLATE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ERDAFITINIB vs ERTUGLIFLOZIN PIDOLATE: Safety Overview

Metric ERDAFITINIB ERTUGLIFLOZIN PIDOLATE
Total FAERS Reports 1,106 681
Deaths Reported 315 4
Death Rate 28.5% 0.6%
Hospitalizations 226 128
Average Patient Age 66.6 yrs 57.0 yrs
% Female Patients 37.9% 56.1%
FDA Approval Date Apr 12, 2019 N/A
Manufacturer Janssen Products LP Merck Sharp & Dohme LLC
Route ORAL ORAL
Marketing Status Prescription N/A